Form 4: Ocular Therapeutix Director Adrienne Graves Granted Significant Equity Awards

Ocular Therapeutix, Inc. Director Adrienne L. Graves was granted 14,000 restricted stock units and 44,000 stock options on June 11, 2025, aligning her interests with shareholders.

Summary

• Adrienne L. Graves, a Director of Ocular Therapeutix, Inc. (OCUL), acquired 14,000 shares of common stock through a grant of Restricted Stock Units (RSUs) on June 11, 2025.
• Each RSU represents a right to receive one share of the company's common stock, granted under the 2021 Stock Incentive Plan.
• These RSUs will vest 100% on the first anniversary of the grant date (June 11, 2026) or, if earlier, immediately prior to the next annual meeting of stockholders, subject to continued service on the board.
• Following this transaction, Ms. Graves beneficially owns 50,000 shares of common stock directly.
• Additionally, Ms. Graves was granted 44,000 stock options on June 11, 2025, with an exercise price of $8.82 per share.
• These stock options will vest 100% on the first anniversary of the grant date (June 11, 2026) or, if earlier, immediately prior to the next annual meeting of stockholders, subject to continued service on the board.
• The options have an expiration date of June 10, 2035.
• Following this transaction, Ms. Graves beneficially owns 44,000 stock options directly.
• A Power of Attorney was executed on June 11, 2025, authorizing specific individuals to handle SEC filings on behalf of Ms. Graves.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as an insider is receiving equity, which generally aligns their interests with shareholders. There are no negative financial implications or red flags in this specific filing.

Positives

• The grant of 14,000 Restricted Stock Units (RSUs) and 44,000 stock options to Director Adrienne L. Graves aligns her interests with those of shareholders, as her compensation is tied to the company's future performance.
• The acquisition of equity by a director, even through a grant, can signal confidence in the company's future prospects and commitment to its long-term success.

Risks

• The vesting of both the 14,000 RSUs and 44,000 stock options is contingent upon Adrienne L. Graves' continued service on the Company's board of directors. If her service ceases before the vesting date, the unvested awards would be forfeited.

Future Outlook

The vesting schedules for the granted RSUs and stock options indicate that Adrienne L. Graves' full ownership of these awards is contingent upon her continued service on the board of directors for at least one year from the grant date or until the next annual meeting of stockholders, whichever is earlier. This implies an expectation of her continued involvement with the company.

Industry Context

Equity grants, including Restricted Stock Units (RSUs) and stock options, are a common form of compensation for directors and executives in the biotechnology and pharmaceutical industries. This practice aims to align their long-term interests with shareholder value creation and is a standard component of compensation packages within the sector.

Comparison to Industry Standards

• The use of RSUs and stock options as part of director compensation is a standard practice across many industries, particularly in high-growth sectors like biotechnology.
• The specific number of units (14,000 RSUs) and options (44,000) and the exercise price ($8.82) would typically be benchmarked against peer companies of similar market capitalization and stage of development within the biopharmaceutical industry to ensure competitive and appropriate compensation. However, this document does not provide specific peer data for a direct comparison.

Corporate Governance

Stakeholder Impact

• Shareholders: The equity grants align the director's financial interests with the long-term performance of the company, potentially encouraging decisions that enhance shareholder value.

Next Steps

• The 14,000 Restricted Stock Units (RSUs) are expected to vest on June 11, 2026, or earlier, prior to the next annual meeting of stockholders, subject to continued service.
• The 44,000 stock options are expected to vest on June 11, 2026, or earlier, prior to the next annual meeting of stockholders, subject to continued service.

Key Dates

Keywords

Ocular Therapeutix, OCUL, SEC Form 4, Insider Transaction, Restricted Stock Units, RSUs, Stock Options, Equity Grant, Director Compensation, Beneficial Ownership